FrancophonIA/ELRC3.0 huggingface dataset:
English: Tablet core: anhydrous lactose, croscarmellose sodium, hypromellose (3 mPa.s), microcrystalline cellulose, magnesium stearate.
Danish: Tabletkernen: vandfri lactose, croscarmellosenatrium, hypromellose (3 mPa.s), mikrokrystallinsk cellulose, magnesiumstearat.
English: General disorders and administration site conditions
Danish: Almenesymptomer og reaktioner på administationsstedet
English: Oxaliplatin 130 mg/m intravenous 2 hr
Danish: Oxaliplatin 130 mg/m2 intravenøs 2 timer
English: In first-line treatment the median progression-free survival in the intent-to-treat population was 5.8 months (95%CI 5.1 - 6.2 months) for capecitabine monotherapy and 7.8 months (95%CI 7.0 - 8.3 months; p=0.0002) for XELIRI.
Danish: I 1. linjebehandlingen var den mediane progressionsfri overlevelse i intent-to-treat-populationen 5,8 måneder (95 % konfidensinterval 5,1-6,2 måneder) for capecitabin-monoterapi og 7,8 måneder (95 % konfidensinterval 7,0 -8,3 måneder; p = 0,0002) for XELIRI.
English: The primary efficacy analyses in the per protocol population demonstrated non-inferiority in overall survival for capecitabine- vs 5-FU-based regimens (hazard ratio 0.86; 95% CI 0.8 - 0.99) and for oxaliplatin- vs cisplatin-based regimens (hazard ratio 0.92; 95% CI 0.80 - 1.1).
Danish: Den primære effektanalyse i per protokolpopulationen demonstrerede non-inferioritet i samlet overlevelse for capecitabin versus 5-FU regimerne (hazard ratio 0,86; 95 %konfidensinterval 0,80,99) og for oxaliplatin mod cisplatinbaserede regimer (hazard ratio 0,92; 95 % konfidensinterval 0,80 - 1,1).
English: Pulmonary embolism, Pneumothorax, Haemoptysis, Asthma, Dyspnoea exertional
Danish: Pneumothorax, Hæmoptyse, Asthma,
English: Full dose 1000 mg/m2
Danish: Fuld dosis 1.000 mg/m2
English: Thrombophlebitis Deep vein thrombosis, Hypertension,
Danish: Thromboflebitis Dyb venethrombose, Hypertension, Petekkier,
English: This leaflet was last revised in <{MM/YYYY}><{month YYYY}>.
Danish: Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ} Andre informationskilder
English: Rare side effects (may affect up to 1 in 1,000 people) include: narrowing or blockage of tear duct (lacrimal duct stenosis) liver failure inflammation leading to dysfunction or obstruction in bile secretion (cholestatic hepatitis) specific changes in the electrocardiogram (QT prolongation) certain types of arrhythmia (including ventricular fibrillation, torsade de pointes, and bradycardia) eye inflammation causing eye pain and possibly eyesight problems inflammation of the skin causing red scaly patches due to an immune system illness
Danish: Sjældne bivirkninger (kan påvirke op til 1 ud af 1.000 personer): · forsnævring eller blokering af tårekanalen, · leversvigt, · betændelse der medfører, at kroppens udskillelse af galde nedsættes eller ophører (kolestatisk hepatitis), · bestemte ændringer i EKG'et (QT-forlængelse), · bestemte former for forstyrrelser i hjerterytmen (ventrikelflimren, torsades de pointes og bradykardi), · inflammation i øjet, der medfører smerter i øjet og muligvis problemer med synet, · inflammation i huden, der medfører røde skællende pletter på grund af en sygdom i immunsystemet.
English: In combination with docetaxel, the recommended starting dose of capecitabine in the treatment of metastatic breast cancer is 1250 mg/m2 twice daily for 14 days followed by a 7- day rest period, combined with docetaxel at 75 mg/m2 as a 1 hour intravenous infusion every 3 weeks.
Danish: I kombination med docetaxel er den anbefalede initialdosis af capecitabin til behandling af metastatisk brystkræft 1.250 mg/m2 to gange dagligt i 14 dage efterfulgt af 7 dages pause, kombineret med docetaxel 75 mg/m2 givet som 1 times intravenøs infusion hver 3. uge.
English: Parameter: Progression-free Survival EPP
Danish: Parameter: Progressionsfri overlevelse EPP
English: Table 2 Standard and reduced dose calculations according to body surface area for a starting dose of capecitabine of 1000 mg/m2
Danish: Tabel 2 Beregning af standard- og reducerede doser ud fra legemsoverfladeareal for en initialdosis af capecitabin på 1.000 mg/m2
English: • Tablet coating: hypromellose (3 mPa.s), titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172) and talc.
Danish: Tabletovertrækket: hypromellose (3 mPa.s), titandioxid (E171), gul jernoxid (E172), rød jernoxid (E172) og talcum.
English: +Neutropenia, +Leucopenia, Anaemia, +Neutropenic fever, Thrombocytopenia
Danish: Blod og lymfesystem +Neutropeni, +Leukopeni, +Anæmi, +Neutropenisk feber, Trombocytopeni
English: Tablet coating: hypromellose, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172), talc.
Danish: Tabletovertrækket hypromellose, titandioxid (E171), gul jernoxid (E172) rød jernoxid (E172), talcum.
English: An analysis of safety data in patients treated with capecitabine monotherapy (colorectal cancer) with baseline renal impairment showed an increase in the incidence of treatment-related grade 3 and 4 adverse reactions compared to patients with normal renal function (36% in patients without renal impairment n=268, vs. 41% in mild n=257 and 54% in moderate n=59, respectively) (see section 5.2).
Danish: 4.2, 4.4 og 5.2) En analyse af sikkerhedsdata fra patienter, som fik capecitabin-monoterapi (kolorektalkræft) og som havde nyreinsufficiens ved baseline, viste, at der var en stigning i hyppigheden af behandlingsrelaterede bivirkninger, grad 3 og 4, sammenlignet med patienter med normal nyrefunktion (36 % hos patienter uden nyreinsufficiens n=268 vs. henholdsvis 41 % hos patienter med let nyreinsufficiens n=257 og 54 % hos patienter med moderat nyreinsufficiens n=59) (se pkt.
English: There is no relevant use of capecitabine in the paediatric population in the indications colon, colorectal, gastric and breast cancer.
Danish: Det er ikke relevant at anvende capecitabin til indikationerne kolonkræft, kolorektalkræft, ventrikelkræft og brystkræft hos den pædiatriske population.
English: The analysis for the secondary endpoint of RFS supports these results with a HR of 0.78 (95% CI=[0.67; 0.92]; p=0.0024) for XELOX vs. 5-FU/LV.
Danish: Analysen for det sekundære endepunkt, relapsfri overlevelse, støtter dissse resultater med en hazard ratio på 0,78 (95 % konfidensinterval = [0,67; 0,92], p = 0,0024) for XELOX versus 5FU/LV.
English: The XELIRI regimens included capecitabine 1000 mg/m2 twice daily on days 1 to 14 of a three-week cycle combined with irinotecan 250 mg/m2 on day1.
Danish: XELIRI-regimerne inkluderede capecitabin 1.000 mg/m2 2 gange dagligt på dag 1-14 i en serie på 3 uger kombineret med irinotecan 250 mg/m2
English: In addition to the above, when Xeloda is used alone, very common side effects, which may affect more than 1 in 10 people are:
Danish: Udover dette kan Xeloda, når det anvendes alene, have følgende meget almindelige bivirkninger, som kan påvirke flere end 1 ud af 10 personer: · mavesmerter · udslæt, tør eller kløende hud · træthed · appetitløshed
English: Table 1 Standard and reduced dose calculations according to body surface area for a starting dose of capecitabine of 1250 mg/m2
Danish: Tabel 1 Beregning af standard og reducerede doser ud fra legemsoverfladeareal for en initialdosis af capecitabin på 1.250 mg/m2
English: • Diarrhoea: if you have an increase of 4 or more bowel movements compared to your normal bowel movements each day or any diarrhoea at night.
Danish: STOP øjeblikkeligt med at tage Xeloda og kontakt lægen, hvis du får nogle af følgende symptomer: · Diarré: hvis du har en øgning på 4 eller flere afføringer om dagen sammenlignet med dit normale antal daglige afføringer, eller hvis du får diarré om natten.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 02 February 2001
Danish: DATO FOR FØRSTE MARKEDSFØRINGSTILLADELSE/FORNYELSE AF TILLADELSEN
English: • Hand-and-foot skin-reaction: if you have pain, swelling, redness or tingling of hands and/or feet
Danish: · Hudsymptomer på hænder og fødder: hvis du har smerter, hævelse, rødme eller prikken i hænder og/eller fødder.
English: If the calculated creatinine clearance decreases during treatment to a value below 30 ml/min, Xeloda should be discontinued.
Danish: Xeloda bør seponeres, hvis den beregnede creatininclearance under behandling falder til et niveau under 30 ml/min.
English: Herpes viral infection, Nasopharyngitis, Lower respiratory tract infection
Danish: Herpes viral infektion, Nasofaryngitis, Infektion i de nedre luftveje
English: Given as monotherapy, the recommended starting dose for capecitabine in the adjuvant treatment of colon cancer, in the treatment of metastatic colorectal cancer or of locally advanced or metastatic breast cancer is 1250 mg/m2 administered twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 14 days followed by a 7-day rest period.
Danish: Den anbefalede initialdosis ved capecitabin-monoterapi, til adjuverende behandling af kolonkræft, til behandling af metastatisk kolorektalkræft eller af lokalt fremskreden eller metastatisk brystkræft er 1.250 mg/m2 administreret to gange dagligt (morgen og aften, svarende til en daglig dosis på
English: For Arm B, the XELIRI regimen used capecitabine 1000 mg/m2 twice daily for 14 days + irinotecan 250 mg/m2 on day 1.
Danish: I arm-B bestod det anvendte XELIRI-regime af 1.000 mg/m2 capecitabin 2 gange dagligt i 14 dage plus 250 mg/m2 irinotecan på dag 1.
English: Japanese patients (n=18) had about 36% lower Cmax and 24% lower AUC for capecitabine than Caucasian patients (n=22).
Danish: Etniske faktorer Efter oral administration af 825 mg/m2 capecitabin to gange dagligt i 14 dage, havde patienter af japansk oprindelse (n=18) omkring 36 % lavere Cmax og 24 % lavere AUC for capecitabin end patienter af kaukasisk oprindelse (n=22).
English: Rash, Alopecia, Erythema, Dry skin, Pruritus, Skin hyperpigmentation, Rash macular, Skin desquamation, Dermatitis, Pigmentation disorder, Nail disorder
Danish: Alopeci, Erythem, Tør hud, Pruritus, Hyperpigmenteri ng af huden, Makuløst udslæt, Afskalning af huden,
English: Monotherapy with capecitabine in adjuvant colon cancer Data from one multicentre, randomised, controlled phase III clinical trial in patients with stage III (Dukes' C) colon cancer supports the use of capecitabine for the adjuvant treatment of patients with colon cancer (XACT Study; M66001).
Danish: Adjuverende monoterapi med capecitabin ved kolonkræft Data fra et randomiseret, kontrolleret, klinisk fase III-multicenterstudie hos patienter med kolonkræft i stadium III (Dukes' stadium C) støtter anvendelsen af Xeloda som adjuverende behandling af patienter med kolonkræft (XACT-Studie; M66001).
English: In a randomised, controlled phase III study (CAIRO), the effect of using capecitabine at a starting dose of 1000 mg/m2 for 2 weeks every 3 weeks in combination with irinotecan for the first-line treatment of patients with metastatic colorectal cancer was studied.
Danish: I et randomiseret, kontrolleret fase III-studie (CAIRO) blev effekten af capecitabin ved anvendelse af en initialdosis på 1.000 mg/m2 i 2 uger hver 3. uge i kombination med irinotecan som 1.
English: You must not breast-feed if you are taking Xeloda and for 2 weeks after the last dose.
Danish: Du må ikke tage Xeloda, hvis du er gravid eller tror du er det. Du må ikke amme, hvis du tager Xeloda og i 2 uger efter sidste dosis.
English: Herpes zoster, Urinary tract infection, Oral candidiasis, Upper respiratory tract infection , Rhinitis, Influenza, +Infection, Oral herpes
Danish: Herpes zoster, Urinvejsinfektion, Oral candidiasis, Øvre luftvejsinfektion, Rhinitis,
English: Xeloda is indicated for the treatment of: -for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer (see section 5.1).
Danish: -for den adjuverende behandling af patienter, som er opereret for stadium III (Dukes stadium C) kolonkræft (se pkt.
English: Common side effects (may affect up to 1 in 10 people) include: decrease in blood sodium, magnesium or calcium, increase in blood sugar nerve pain ringing or buzzing in the ears (tinnitus), loss of hearing vein inflammation hiccups, change in voice pain or altered/abnormal sensation in the mouth, pain in the jaw sweating, night sweats muscle spasm difficulty in urination, blood or protein in the urine
Danish: Almindelige bivirkninger (kan påvirke op til 1 ud af 10 personer): · nedsat indhold af natrium, magnesium og kalk i blodet, stigning i blodsukker, · nervesmerter, · ringen eller summen i ørerne (tinnitus), høretab, · betændelse i venerne, · hikke, ændret stemme, · smerter eller ændret/unormal følelse i munden, smerter i kæben, · sveden, nattesved, · muskelkramper, · problemer ved vandladning, blod i urinen, skummende urin (protein i urinen), · blå mærker eller reaktioner, hvor du får en indsprøjtning (skyldes anden medicin, der gives samtidig via indsprøjtning).
English: In this trial, 1987 patients were randomised to treatment with capecitabine (1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period and given as 3-week cycles for 24 weeks) or 5-FU and leucovorin (Mayo Clinic regimen: 20 mg/m2 leucovorin IV followed by 425 mg/m2 intravenous bolus 5-FU, on days 1 to 5, every 28 days for 24 weeks).
Danish: I dette studie blev 1.987 patienter randomiseret til behandling med capecitabin (1.250 mg/m2 to gange dagligt i 2 uger, efterfulgt af en uges pause, givet som 3-ugers serier i 24 uger) eller til behandling med 5-FU og leucovorin (Mayo Clinic-regime: 20 mg/m2 leucovorin i.v., efterfulgt af 425 mg/m2 intravenøs 5-FU som bolus på dag 1 til 5, hver 28.
English: What Xeloda is and what it is used for
Danish: Xeloda er indiceret som behandling af
English: Full dose 1250 mg/m2
Danish: Fuld dosis 1.250 mg/m2
English: Xeloda 500 mg film-coated tablets Each film-coated tablet contains 500 mg capecitabine
Danish: Xeloda 500 mg filmovertrukne tabletter Hver tablet indeholder 500 mg capecitabine
English: 10.0 and 8.9 months; p=0.64, overall survival 25.7 and 27.5 months; p=0.55 and response rates 45.5 and 39.8%; p=0.32 for FOLFIRI-Bev and XELIRI-Bev, respectively.
Danish: For henholdsvis FOLFIRI plus bevacizumab og XELIRI plus bevacizumab var den mediane progressionfri overlevelse 10,0 og 8,9 måneder; p = 0,64, samlet overlevelse var 25,7 og 27,5 måneder; p = 0,55, og responsrater 45,5 % og 39,8 %; = 0,32.
English: Dose level 1000 mg/m
Danish: Dosisniveau på 1.000 mg/m
English: • Grade 2 -1st appearance
Danish: · Grad 2 ved 1. forekomst
English: PVC/PVDC blisters
Danish: 6.5 Emballagetype og pakningsstørrelser PVC/PVDC blistre
English: How to take Xeloda
Danish: Sådan skal du tage Xeloda
English: Combination treatment consisted of first-line capecitabine (1000 mg/m2 twice daily for 14 days) combined with irinotecan (250 mg /m2 on day 1) (XELIRI) and second-line capecitabine (1000 mg/m2 twice daily for 14 days) plus oxaliplatin (130 mg/m2 on day 1).
Danish: Kombinationsbehandlingen bestod af 1. linjebehandling med capecitabin (1.000 mg/m2 to gange daglig i 14 dage) kombineret med irinotecan (250 mg/m2 på dag 1) (XELIRI) og 2. linjebehandling med capecitabin (1.000 mg/m2 to gange dagligt i 14 dage) plus oxaliplatin (130 mg/m2
English: Xeloda 500 mg film-coated tablets.
Danish: Xeloda 500 mg filmovertrukne tabletter.
English: Hypokalaemia, Appetite disorder, Malnutrition, Hypertriglyceridaemia,
Danish: Diabetes, Hypokaliæmi, Appetitforstyrrelser, Underernæring, Hypertriglyceridæmi
English: 1, every 3 weeks).
Danish: dag i 24 uger).
English: 24.6, 2.03 and 36.3.
Danish: 4.3 og 4.4).
English: Pain in jaw , Muscle spasms, Trismus, Muscular weakness
Danish: Kæbesmerter, Muskelspasmer, Trismus, Muskelsvaghed
English: The incidence of grade 3 or 4 adverse reactions in patients with moderate renal impairment (creatinine clearance 30-50 ml/min) is increased compared to the overall population (see sections 4.2 and 4.3).
Danish: Sammenlignet med hele populationen er hyppigheden af bivirkninger af grad 3 eller 4 forøget hos patienter med moderat nyreinsufficiens (creatininclearance 30 - 50 ml/min) (se pkt.
English: • Grade 4 -1st appearance
Danish: · Grad 4 ved 1. forekomst
English: In this trial, 160 patients were randomised to treatment with capecitabine (1000 mg/m2 twice daily for 2 weeks followed by a 7-day rest period) and cisplatin (80 mg/m2 as a 2-hour infusion every 3 weeks).
Danish: I dette studie blev 160 patienter randomiseret til behandling med capecitabin (1.000 mg/m2 to gange dagligt i 2 uger efterfulgt af 7 dages pause) og cisplatin (80 mg/m2 som en 2
English: Body System Very Common
Danish: Meget almindelig
English: • Grade 3 -1st appearance
Danish: · Grad 3 ved 1. forekomst
English: Dose level 1250 mg/m
Danish: Dosisniveau på 1.250 mg/m
English: Reduced dose 950 mg/m2
Danish: Reduceret dosis 950 mg/m2
English: •h/ml were 7.75, 7.24,
Danish: AUC0-¥ værdierne (mg·time/ml var 7,75; 7,24; 24,6; 2,03 og 36,3.
English: History of severe and unexpected reactions to fluoropyrimidine therapy, Hypersensitivity to capecitabine or to any of the excipients listed in section 6.1 or fluorouracil, In patients with known complete absence of dihydropyrimidine dehydrogenase (DPD) activity (see section 4.4),
Danish: 6.1 eller fluoruracil, · Patienter med kendt fuldstændig mangel på dihydropyrimidindehydrogenase- (DPD-) aktivitet (se pkt.
English: Reduced dose 625 mg/m2
Danish: Reduceret dosis 625 mg/m2
English: NAME OF THE MEDICINAL PRODUCT Xeloda 500 mg film-coated tablets Capecitabine
Danish: LÆGEMIDLETS NAVN Xeloda 500 mg filmovertrukne tabletter Capecitabin
English: • lumps under the skin (lipoma) decreases in blood cells including platelets, thinning of blood (seen in tests) allergy diabetes, decrease in blood potassium, malnutrition, increased blood triglycerides confusional state, panic attacks, depressed mood, decreased libido
Danish: (også i munden), influenza, maveinfluenza, tandbylder, · knuder under huden (lipom), · fald i blodtal, inklusive blodplader, ”fortyndet” blod (kan ses i blodprøve) · allergi · sukkersyge, nedsat indhold af kalium i blodet, underernæring, øget niveau af triglycerider i blodet, · forvirring, panikanfald, depression, nedsat sexlyst, · talebesvær, dårlig hukommelse, koordinationsforstyrrelser, balanceforstyrrelser, besvimelse,
English: NAME OF THE MEDICINAL PRODUCT Xeloda 150 mg film-coated tablets Capecitabine
Danish: LÆGEMIDLETS NAVN Xeloda 150 mg filmovertrukne tabletter Capecitabin
English: Intestinal obstruction, Ascites, Enteritis, Gastritis, Dysphagia, Abdominal pain lower, Oesophagitis, Abdominal discomfort,
Danish: Enteritis, Gastritis, Dysfagi, Nedre abdominale smerter,
English: 3 weeks), and bevacizumab (7.5 mg/kg as a 30 to 90 minute infusion on day 1 every 3 weeks ; 127 patients were randomised to treatment with capecitabine (1000 mg/m2 twice daily for two weeks followed by a 7-day rest period), oxaliplatin (130 mg/m as a 2 hour infusion on day 1 every 3 weeks), and bevacizumab (7.5 mg/kg as a 30 to 90 minute infusion on day 1 every 3 weeks).
Danish: 127 patienter blev randomiseret til behandling med capecitabin (1.000 mg/m2 2 gange dagligt i to uger efterfulgt af 7 dages pause), oxaliplatin (130 mg/m2 som infusion over 2 timer på dag 1 hver tredje uge) og bevacizumab (7,5 mg/kg som infusion over 30 til 90 minutter på dag 1 hver tredje uge).
English: 120 Patients were randomised to a modified XELIRI regimen with capecitabine 800 mg/m2 twice daily for two weeks followed by a 7-day rest period), irinotecan (200 mg/m2 as a 30 minute infusion on day 1 every
Danish: 120 patienter blev randomiseret til at få et modficeret XELIRI-regime med capecitabin (800 mg/m2 2 gange dagligt i to uger efterfulgt af 7 dages pause), irinotecan (200 mg/m2 som infusion over 30 minutter på dag 1 hver tredje uge) og bevacizumab (7,5 mg/kg som infusion over 30 til 90 minutter på dag 1 hver tredje uge).
English: Diabetes,
Danish: Feber,
English: Xeloda 150 mg film-coated tablets
Danish: Xeloda 150 mg filmovertrukne tabletter
English: Xeloda 500 mg film-coated tablets Each 500 mg film-coated tablet contains 52 mg anhydrous lactose.
Danish: Hver 500 mg filmovertrukket tablet indeholder 52 mg lactose, vandfri.
English: Xeloda 150 mg film-coated tablets Each 150 mg film-coated tablet contains 15.6 mg anhydrous lactose.
Danish: Hver 150 mg filmovertrukket tablet indeholder 15,6 mg lactose, vandfri.
English: Xeloda 150 mg film-coated tablets Xeloda 500 mg film-coated tablets capecitabine
Danish: Xeloda 150 mg filmovertrukne tabletter Xeloda 500 mg filmovertrukne tabletter capecitabin
English: Radiotherapy: the MTD of capecitabine alone using the intermittent regimen is 3000 mg/m2 per day, whereas, when combined with radiotherapy for rectal cancer, the MTD of capecitabine is 2000 mg/m2
Danish: MTD for capecitabin alene ved anvendelse af det intermitterende regime er 3.000 mg/m2 pr. dag, hvorimod MTD er 2.000 mg/m2 pr. dag, når capecitabin kombineres med stråleterapi ved kolorektalkræft, enten ved anvendelse af en kontinuerlig behandling eller anvendt dagligt fra mandag til fredag under en seks ugers serie med stråleterapi.
English: Febrile neutropenia, Pancytopenia, Granulocytopenia, Thrombocytopenia, Leukopenia, Haemolytic anaemia, International Normalised Ratio (INR) increased/Prothrombin time prolonged
Danish: Febril neutropeni, Pancytopeni, Granulocytopeni, Thrombocytopeni, Leukopeni, Hæmolytisk anæmi,
English: Gastrointestinal disorders
Danish: Øvre gastrointestinal blødning,
English: Oedema, Chills, Influenza like illness, Rigors, Body temperature increased
Danish: Kuldegysninger, Influenzalignende symptomer, Kulderystelser, Øget kropstemperatur
English: Upper gastrointestinal haemorrhage, Mouth ulceration, Gastritis, Abdominal distension, Gastroesophageal reflux disease, Oral pain, Dysphagia, Rectal haemorrhage, Abdominal pain lower, Oral dysaesthesia, Paraesthesia oral, Hypoaesthesia oral, Abdominal discomfort
Danish: Rektal blødning, Nedre abdominalsmerter, Oral dysæstesi, Oral paræstesi, Oral hypoæstesi, Abdominal ubehag
English: Lacrimation increased Visual disorders, Dry eye, Eye pain, Visual impairment, Vision blurred
Danish: Øget tåresekretion Synsforstyrrelser, Tørre øjne,
English: Appetite decreased Hypokalaemia, Hyponatraemia, Hypomagnesaemia,
Danish: Hypokaliæmi, Hyponatriæmi, Hypomagnesiæmi, Hypokalcæmi, Hyperglycæmi
English: What Xeloda is and what it is used for What you need to know before you take Xeloda How to take Xeloda
Danish: Det skal du vide, før du begynder at tage Xeloda Sådan skal du tage Xeloda Bivirkninger
English: - EOF: epirubicin (50 mg/m2 as a bolus on day 1 every 3 weeks), oxaliplatin (130 mg/m2 given as a 2 hour infusion on day 1 every three weeks), and 5-FU (200 mg/m2 daily given by continuous infusion via a central line).
Danish: - EOF: epirubicin (50 mg/ m2 som bolus på dag 1 hver 3. uge), oxaliplatin (130 mg/m2 som en to-timers infusion på dag 1 hver 3. uge) og 5-FU (200 mg/m2 dagligt givet som kontinuerlig infusion via en central linje).
English: 150 mg 500 mg
Danish: Dosis pr. dosering (mg) 150 mg 500 mg
English: In this trial, 944 patients were randomised to 3-week cycles for 24 weeks with capecitabine (1000 mg/m2 twice daily for 2 weeks followed by a 1-week rest period) in combination with oxaliplatin (130 mg/m2 intravenous infusion over 2-hours on day 1 every 3 weeks); 942 patients were randomised to bolus 5-FU and leucovorin.
Danish: I dette studie blev 944 patienter randomiseret til 3-ugers-cykler i 24 uger med capecitabin (1.000 mg/m2 to gange dagligt i 2 uger, efterfulgt af én uges pause) i kombination med oxaliplatin (130 mg/m2 intravenøs infusion over 2 timer på dag 1 hver 3.uge).
English: - ECX: epirubicin (50 mg/m2 as a bolus on day 1 every 3 weeks), cisplatin (60 mg/m2 as a two hour infusion on day 1 every 3 weeks), and capecitabine (625 mg/m2 twice daily continuously).
Danish: - ECX: epirubicin (50 mg/ m2 som bolus på dag 1 hver 3. uge), cisplatin (60 mg/m2 som en totimers infusion på dag 1 hver 3. uge) og capecitabin (625 mg/m2 to gange dagligt givet kontinuerligt).
English: Tel: +420 - 2 20382111
Danish: Roche s. r. o. Tel: +420 - 2 20382111